# Viking Therapeutics, Inc. stock analysis

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatoh

## Market evidence and data freshness

The public preview recorded Viking Therapeutics, Inc. at 33.03 USD on 2026-09-28T20:00:00.000Z and marked the quote as delayed. This observation is not a trading signal.
Available price history spans 2021-09-30 through 2026-09-25 across 1239 observations; the listed source is CommonQuant Parquet archive backed by Yahoo Finance delayed data. The history end date differs from the latest quote date.

## What should I review before buying Viking Therapeutics, Inc. stock?

Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.

## Inside the full report

- Valuation
- Growth
- Financial health
- Ownership
- Research

Sign in to open the full analysis. Paid plans use included reports first, then 50 credits per additional report. Reports outside your included market also cost 50 credits. Credit access lasts 72 hours, including revisits.

[Read the report](https://commonquant.ai/markets/vktx)